BioCatalystWatch
ATRAWorkspace / ATRA / OverviewCompany library
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (ATRA)

Website

Price
Market cap
Next catalystMar 31, 2027Tabelecleucel (tab-cel / EBVALLO) — EBV+ PTLD · Regulatory decisionCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Partner / License out

History / paused

Cell therapy

EBV antigens

PreINDP1P2P3FilingApproved

Cell therapy

Mesothelin (MSLN)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ATRA PR & News

PR & News

ATRA SEC archive